Novo Nordisk's (NYSE: NVO) shares have dropped significantly over the past year, partly due to clinical setbacks in its core GLP-1 portfolio. However, the Denmark-based pharmaceutical leader has been ...

Novo Nordisk has launched a rival bid for U.S. obesity biotech firm Metsera, directly challenging an existing offer from Pfizer. The move, announced Thursday, escalates the competition between the two ...

Pfizer's revenue rose by 10% last quarter, exceeding market expectations. The drugmaker has been cutting costs, which has paid off at the bottom line. However, the industry is feeling government ...

Pfizer has been trying to get in on the billion-dollar weight loss drug market. Novo Nordisk initially dominated this market but has been losing ground to Eli Lilly. 10 stocks we like better than ...

(Corrects paragraph 1 to say Pfizer is suing Metsera shareholders, not its own shareholders) (Reuters) -Pfizer Inc said on Monday it has filed a second lawsuit against Metsera and its controlling ...